Supporting end-to-end research and development of large molecule drugs including, biologics, antibody-drug conjugates, biosimilars, and more

New Fibrant Line Changes the Game of Fiber Grafting

Estar Medical, the maker of Eclipse PRP® and Tropocells®, has signed an exclusive long-term marketing and distribution agreement with Aesthetic Management Partners, LLC (AMP), to sell its PRP products in the U.S. market.

The acquisition of TheraCell, Inc. will expand access for two best-in-class product portfolios and build upon Isto's continued commitment to putting patients and their surgical champions first.

Companies have also entered into a joint development agreement which will merge technologies with the aim to bring innovative products for consumer electronics market.

Benjamin L. England & Associates, an FDA and a Customs Law Practice Strengthens Resources

Phase II Clinical Trial Initiated for ExoFlo Extracellular Vesicles in the Treatment of COVID-19

Innovative USB extends established temperature management service for sponsors and patients

Isto Biologics, the Orthobiologics Pioneers, Named 2020 Top Orthopedic Solution Provider

Open invitation to the biopharma industry to share insights

AASCP meets with AAEM to discuss and spearhead Biologic Safety standards in Regenerative Medicine.

Alliance for Stem Cell Therapy Now Ms. Janet Marchibroda will moderate the Safety industry panel hosted by AASCP in Miami on November 2, 2019 and will be broadcast live.

Agreement further supports Parametrics' and DePuy Synthes' shared commitment to a comprehensive sports medicine procedural focus as physicians care for a broader patient population

Center Provides Scientific Education and Training for Regenerative Medicine

This three-part webinar series reviews the key considerations for design and conduct of a development plan for a monoclonal antibody (mAb) product.

Candidacy analysis for pipeline agents reveals that JAK inhibitors, such as Pfizer's PF-0496582, AbbVie's upadacitinib and Incyte's topical ruxolitinib have the most potential upside if approved

The majority of patients started on Xeljanz have failed multiple biologics, but some gastroenterologists see the brand securing a role in the pre-biologic space in the near future, according to the latest quarterly report from Spherix Global Insights

At the heart of key challenges facing biologics laboratories today lies the volume and complexity of data created throughout the scientific process

Factors, such as growing incidence of cancer cases and lifestyle diseases globally, the cost-effectiveness of biosimilars over biologics, and strategic collaboration to develop new biosimilar drugs will increase the market growth during the forecast period.

Presentation to highlight the approaches used in developing consistent cell-based potency assays meeting regulatory expectations (USP <1032> and <1033>) and are suitable for CGMP stability testing

Royal Biologics Launches MAXX™-Fuse, a demineralized bone matrix product derived from 100 percent human bone

50% Commission Offering for Initial Distributors. Amnio-Maxx™ will be used to treat various conditions in orthopedics and sports medicine.

H2Biologics Licenses Worldwide, Exclusive Rights to Develop SD1-Granzyme B Drug Conjugate for Treatment of Mesothelin-expressing Tumors.

Trianni, Inc. is delighted to announce that the Trianni Mouse Platform was granted an Australian Patent. The Trianni Mouse Platform provides the complete human antibody repertoire for the facile isolation of monoclonal antibodies.

Immunotherapeutics field is rapidly advancing at an unprecedented rate, as estimated by IQ4I Research that the immunotherapeutics global market is expected to reach $138.9 billion by 2021.

Analysis results in greater understanding of important biological traits related to crop drought tolerance

Largest European Event for Biologics Returns to Lisbon from 2-6 November

High purity tubing and single use systems manufacturer AdvantaPure has appointed Tony Butler to a new position focusing on single use systems for pharmaceutical and biologics manufacturing. The role arose because of the company's continued growth.

The organisation team of the international Drug-Drug Interaction (DDI) Workshop in Marbach Castle on Lake Constance is happy to report the great acceptance and success of the events series in its fourth year. More than 70 drug development experts and

VENADO represents an entirely new product family in K2M's growing biologics portfolio, already featuring VIKOS® Allograft Systems and VESUVIUSTM Osteobiologic Systems.

Radolfzell, Germany, November 28th 2012: The organisation team of the International DDI Workshop presents the preliminary programme of the DDI 2013 - 4th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Precli

Company Leasing New Office Space, Increasing Workforce Due to Growing Client Portfolio